Key Highlights
- $60 million Series A+ financing round led by Osang Healthcare Co., Ltd.
- Funds to accelerate pivotal trials and support regulatory approvals.
- Allez Health has seven issued patents and over 40 pending patent applications.
- Completed pivotal study with 120 insulin users.
- Plans to commercialize in multiple global markets.
Source: Business Wire
Notable Quotes
- “We believe that person-centric health is critical for optimal health solutions. We aim to bring to market a sensor that combines access, affordability, and reliable performance, because when it comes to an individual’s health, no one should have to choose between price and performance.” – Leif Bowman, co-founder and CEO at Allez Health
- “Since the founding of Allez Health, we have been impressed by their progress and are excited to officially forge a strong collaboration with them. Their innovative design and technical advances, coupled with Osang’s world-class manufacturing capability and global reach, will bring meaningful access to world-class CGM technology for millions of people with diabetes as well as the broader wellness market.” – Dr. Chulhun Kang, CEO at Osang Healthcare
SoHC's Take
The recent $60 million Series A+ financing secured by Allez Health Inc. underscores the company’s rapid advancement in the CGM biosensor market. With the strategic backing of Osang Healthcare, Allez Health is well-positioned to overcome regulatory hurdles and expand its manufacturing capabilities. Their impressive portfolio of patents and clinical studies signals strong innovation potential. As Allez Health prepares to commercialize its novel sensor technology globally, it stands to significantly impact the accessibility and affordability of continuous glucose monitoring, benefiting millions in the diabetes and broader wellness markets.
